Hims & Hers Health (NYSE:HIMS) Shares Gap Down After Insider Selling

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) gapped down prior to trading on Tuesday following insider selling activity. The stock had previously closed at $31.35, but opened at $29.90. Hims & Hers Health shares last traded at $29.83, with a volume of 3,359,925 shares.

Specifically, CFO Oluyemi Okupe sold 101,993 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66. Following the completion of the sale, the chief financial officer now directly owns 109,392 shares of the company’s stock, valued at approximately $3,240,191.04. The trade was a 48.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,343 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the transaction, the insider now directly owns 165,254 shares in the company, valued at approximately $4,941,094.60. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent analyst reports. Piper Sandler restated a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Needham & Company LLC started coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.71.

Hims & Hers Health Trading Down 1.1 %

The stock has a market capitalization of $6.63 billion, a P/E ratio of 68.98 and a beta of 1.06. The company’s fifty day simple moving average is $21.14 and its 200 day simple moving average is $19.57.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the previous year, the business earned ($0.04) earnings per share. The firm’s revenue was up 77.1% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. Robeco Institutional Asset Management B.V. bought a new position in shares of Hims & Hers Health in the 3rd quarter worth $604,000. Carnegie Investment Counsel bought a new position in Hims & Hers Health in the third quarter valued at $5,531,000. Royce & Associates LP raised its position in Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Versor Investments LP bought a new stake in Hims & Hers Health during the third quarter worth about $634,000. Finally, International Assets Investment Management LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth about $6,790,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.